Prosight Management, LP Viking Therapeutics, Inc. Transaction History
Prosight Management, LP
- $372 Million
- Q3 2024
A detailed history of Prosight Management, LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 48,000 shares of VKTX stock, worth $2.03 Million. This represents 0.82% of its overall portfolio holdings.
Number of Shares
48,000
Previous 115,000
58.26%
Holding current value
$2.03 Million
Previous $6.1 Million
50.16%
% of portfolio
0.82%
Previous 1.9%
Shares
6 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$431 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$255 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$198 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$89.6 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$79.4 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.25B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...